Mid-term follow-up surgical results in 284 cases of clival chordomas: the risk factors for outcome and tumor recurrence
-
Published:2021-10-08
Issue:
Volume:
Page:
-
ISSN:0344-5607
-
Container-title:Neurosurgical Review
-
language:en
-
Short-container-title:Neurosurg Rev
Author:
Bai Jiwei, Li Mingxuan, Shi Jianxin, Jing Liwei, Zhai Yixuan, Zhang Shuheng, Wang Junmei, Zhao Peng, Li Chuzhong, Gui Songbai, Zhang YazhuoORCID
Abstract
Abstract
Objective
Skull base chordoma (SBC) is rare and one of the most challenging diseases to treat. We aimed to assess the optimal timing of adjuvant radiation therapy (RT) and to evaluate the factors that influence resection and long-term outcomes.
Methods
In total, 284 patients with 382 surgeries were enrolled in this retrospective study. Postsurgically, 64 patients underwent RT before recurrence (pre-recurrence RT), and 47 patients underwent RT after recurrence. During the first attempt to achieve gross-total resection (GTR), when the entire tumor was resected, 268 patients were treated with an endoscopic midline approach, and 16 patients were treated with microscopic lateral approaches. Factors associated with the success of GTR were identified using χ2 and logistic regression analyses. Risk factors associated with chordoma-specific survival (CSS) and progression-free survival (PFS) were evaluated with the Cox proportional hazards model.
Results
In total, 74.6% of tumors were marginally resected [GTR (40.1%), near-total resection (34.5%)]. History of surgery, large tumor volumes, and tumor locations in the lower clivus were associated with a lower GTR rate. The mean follow-up period was 43.9 months. At the last follow-up, 181 (63.7%) patients were alive. RT history, histologic subtype (dedifferentiated and sarcomatoid), non-GTR, no postsurgical RT, and the presence of metastasis were associated with poorer CSS. Patients with pre-recurrence RT had the longest PFS and CSS, while patients without postsurgical RT had the worst outcome.
Conclusion
GTR is the goal of initial surgical treatment. Pre-recurrence RT would improve outcome regardless of GTR.
Publisher
Springer Science and Business Media LLC
Subject
Neurology (clinical),General Medicine,Surgery
Reference40 articles.
1. Al-Mefty O (2017) Chordoma. Acta Neurochir 159:1869–1871. https://doi.org/10.1007/s00701-017-3287-9 2. Almefty K, Pravdenkova S, Colli BO, Al-Mefty O, Gokden M (2007) Chordoma and chondrosarcoma: similar, but quite different, skull base tumors. Cancer 110:2457–2467. https://doi.org/10.1002/cncr.23073 3. Bai J, Zhang S, Zhai Y, Wang S, Li M, Li C, Zhao P, Geng S, Gui S, Zhang Y (2020) A series of 62 skull base chordomas in pediatric and adolescent patients: clinical characteristics, treatments, and outcomes. Neurol India 68:1030–1036. https://doi.org/10.4103/0028-3886.294548 4. Bai J, Shi J, Li C, Wang S, Zhang T, Hua X, Zhu B, Koka H, Wu HH, Song L, Wang D, Wang M, Zhou W, Ballew BJ, Zhu B, Hicks B, Mirabello L, Parry DM, Zhai Y, Li M, Du J, Wang J, Zhang S, Liu Q, Zhao P, Gui S, Goldstein AM, Zhang Y, Yang XR (2021) Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival. Nat Commun 12:757. https://doi.org/10.1038/s41467-021-21026-5 5. Beccaria K, Tauziede-Espariat A, Monnien F, Adle-Biassette H, Masliah-Planchon J, Pierron G, Maillot L, Polivka M, Laquerriere A, Bouillot-Eimer S, Gimbert E, Gauchotte G, Coffinet L, Sevestre H, Alapetite C, Bolle S, Thompson D, Bouazza S, George B, Zerah M, Sainte-Rose C, Puget S, Varlet P (2018) Pediatric chordomas: results of a multicentric study of 40 children and proposal for a histopathological prognostic grading system and new therapeutic strategies. J Neuropathol Exp Neurol 77:207–215. https://doi.org/10.1093/jnen/nlx118
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|